Financhill
Sell
12

SLS Quote, Financials, Valuation and Earnings

Last price:
$0.93
Seasonality move :
9.08%
Day range:
$0.94 - $1.09
52-week range:
$0.50 - $1.72
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.21x
Volume:
2.4M
Avg. volume:
1.6M
1-year change:
72.8%
Market cap:
$66.9M
Revenue:
--
EPS (TTM):
-$0.69

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SLS
SELLAS Life Sciences Group
-- -$0.11 -- -57.33% $6.83
AVXL
Anavex Life Sciences
-- -$0.17 -- -54.55% $35.47
GALT
Galectin Therapeutics
-- -- -- -- --
MBOT
Microbot Medical
-- -$0.17 -- -32% --
OGEN
Oragenics
-- -- -- -- --
TCRT
Alaunos Therapeutics
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SLS
SELLAS Life Sciences Group
$0.95 $6.83 $66.9M -- $0.00 0% --
AVXL
Anavex Life Sciences
$11.43 $35.47 $969.4M -- $0.00 0% --
GALT
Galectin Therapeutics
$1.13 -- $70.9M -- $0.00 0% --
MBOT
Microbot Medical
$1.87 -- $31.7M -- $0.00 0% --
OGEN
Oragenics
$0.33 -- $4.1M -- $0.00 0% 1.31x
TCRT
Alaunos Therapeutics
$1.85 -- $3M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SLS
SELLAS Life Sciences Group
-- 1.208 -- --
AVXL
Anavex Life Sciences
-- 1.770 -- --
GALT
Galectin Therapeutics
-- 0.337 -- --
MBOT
Microbot Medical
-- 0.924 -- --
OGEN
Oragenics
-- 2.471 -- --
TCRT
Alaunos Therapeutics
-- 2.996 -- 2.72x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SLS
SELLAS Life Sciences Group
-- -$7.3M -- -- -- -$7.8M
AVXL
Anavex Life Sciences
-- -$14.3M -- -- -- -$6.7M
GALT
Galectin Therapeutics
-- -$9.1M -- -- -- -$8.5M
MBOT
Microbot Medical
-- -$3.3M -- -- -- -$2.8M
OGEN
Oragenics
-- -$2.4M -- -- -- -$2M
TCRT
Alaunos Therapeutics
-- -$1.2M -189.69% -189.69% -28225% -$781K

SELLAS Life Sciences Group vs. Competitors

  • Which has Higher Returns SLS or AVXL?

    Anavex Life Sciences has a net margin of -- compared to SELLAS Life Sciences Group's net margin of --. SELLAS Life Sciences Group's return on equity of -- beat Anavex Life Sciences's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SLS
    SELLAS Life Sciences Group
    -- -$0.10 --
    AVXL
    Anavex Life Sciences
    -- -$0.14 --
  • What do Analysts Say About SLS or AVXL?

    SELLAS Life Sciences Group has a consensus price target of $6.83, signalling upside risk potential of 513.78%. On the other hand Anavex Life Sciences has an analysts' consensus of $35.47 which suggests that it could grow by 214.72%. Given that SELLAS Life Sciences Group has higher upside potential than Anavex Life Sciences, analysts believe SELLAS Life Sciences Group is more attractive than Anavex Life Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLS
    SELLAS Life Sciences Group
    2 0 0
    AVXL
    Anavex Life Sciences
    2 0 0
  • Is SLS or AVXL More Risky?

    SELLAS Life Sciences Group has a beta of 2.407, which suggesting that the stock is 140.73% more volatile than S&P 500. In comparison Anavex Life Sciences has a beta of 0.702, suggesting its less volatile than the S&P 500 by 29.85%.

  • Which is a Better Dividend Stock SLS or AVXL?

    SELLAS Life Sciences Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group pays -- of its earnings as a dividend. Anavex Life Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLS or AVXL?

    SELLAS Life Sciences Group quarterly revenues are --, which are smaller than Anavex Life Sciences quarterly revenues of --. SELLAS Life Sciences Group's net income of -$7.1M is higher than Anavex Life Sciences's net income of -$11.6M. Notably, SELLAS Life Sciences Group's price-to-earnings ratio is -- while Anavex Life Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group is -- versus -- for Anavex Life Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLS
    SELLAS Life Sciences Group
    -- -- -- -$7.1M
    AVXL
    Anavex Life Sciences
    -- -- -- -$11.6M
  • Which has Higher Returns SLS or GALT?

    Galectin Therapeutics has a net margin of -- compared to SELLAS Life Sciences Group's net margin of --. SELLAS Life Sciences Group's return on equity of -- beat Galectin Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SLS
    SELLAS Life Sciences Group
    -- -$0.10 --
    GALT
    Galectin Therapeutics
    -- -$0.18 --
  • What do Analysts Say About SLS or GALT?

    SELLAS Life Sciences Group has a consensus price target of $6.83, signalling upside risk potential of 513.78%. On the other hand Galectin Therapeutics has an analysts' consensus of -- which suggests that it could grow by 873.45%. Given that Galectin Therapeutics has higher upside potential than SELLAS Life Sciences Group, analysts believe Galectin Therapeutics is more attractive than SELLAS Life Sciences Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLS
    SELLAS Life Sciences Group
    2 0 0
    GALT
    Galectin Therapeutics
    0 0 0
  • Is SLS or GALT More Risky?

    SELLAS Life Sciences Group has a beta of 2.407, which suggesting that the stock is 140.73% more volatile than S&P 500. In comparison Galectin Therapeutics has a beta of 0.828, suggesting its less volatile than the S&P 500 by 17.204%.

  • Which is a Better Dividend Stock SLS or GALT?

    SELLAS Life Sciences Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galectin Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group pays -- of its earnings as a dividend. Galectin Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLS or GALT?

    SELLAS Life Sciences Group quarterly revenues are --, which are smaller than Galectin Therapeutics quarterly revenues of --. SELLAS Life Sciences Group's net income of -$7.1M is higher than Galectin Therapeutics's net income of -$11.2M. Notably, SELLAS Life Sciences Group's price-to-earnings ratio is -- while Galectin Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group is -- versus -- for Galectin Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLS
    SELLAS Life Sciences Group
    -- -- -- -$7.1M
    GALT
    Galectin Therapeutics
    -- -- -- -$11.2M
  • Which has Higher Returns SLS or MBOT?

    Microbot Medical has a net margin of -- compared to SELLAS Life Sciences Group's net margin of --. SELLAS Life Sciences Group's return on equity of -- beat Microbot Medical's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SLS
    SELLAS Life Sciences Group
    -- -$0.10 --
    MBOT
    Microbot Medical
    -- -$0.20 --
  • What do Analysts Say About SLS or MBOT?

    SELLAS Life Sciences Group has a consensus price target of $6.83, signalling upside risk potential of 513.78%. On the other hand Microbot Medical has an analysts' consensus of -- which suggests that it could grow by 274.33%. Given that SELLAS Life Sciences Group has higher upside potential than Microbot Medical, analysts believe SELLAS Life Sciences Group is more attractive than Microbot Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLS
    SELLAS Life Sciences Group
    2 0 0
    MBOT
    Microbot Medical
    0 0 0
  • Is SLS or MBOT More Risky?

    SELLAS Life Sciences Group has a beta of 2.407, which suggesting that the stock is 140.73% more volatile than S&P 500. In comparison Microbot Medical has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.099%.

  • Which is a Better Dividend Stock SLS or MBOT?

    SELLAS Life Sciences Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Microbot Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group pays -- of its earnings as a dividend. Microbot Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLS or MBOT?

    SELLAS Life Sciences Group quarterly revenues are --, which are smaller than Microbot Medical quarterly revenues of --. SELLAS Life Sciences Group's net income of -$7.1M is lower than Microbot Medical's net income of -$3.2M. Notably, SELLAS Life Sciences Group's price-to-earnings ratio is -- while Microbot Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group is -- versus -- for Microbot Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLS
    SELLAS Life Sciences Group
    -- -- -- -$7.1M
    MBOT
    Microbot Medical
    -- -- -- -$3.2M
  • Which has Higher Returns SLS or OGEN?

    Oragenics has a net margin of -- compared to SELLAS Life Sciences Group's net margin of --. SELLAS Life Sciences Group's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SLS
    SELLAS Life Sciences Group
    -- -$0.10 --
    OGEN
    Oragenics
    -- -$0.38 --
  • What do Analysts Say About SLS or OGEN?

    SELLAS Life Sciences Group has a consensus price target of $6.83, signalling upside risk potential of 513.78%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 26878.41%. Given that Oragenics has higher upside potential than SELLAS Life Sciences Group, analysts believe Oragenics is more attractive than SELLAS Life Sciences Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLS
    SELLAS Life Sciences Group
    2 0 0
    OGEN
    Oragenics
    0 0 0
  • Is SLS or OGEN More Risky?

    SELLAS Life Sciences Group has a beta of 2.407, which suggesting that the stock is 140.73% more volatile than S&P 500. In comparison Oragenics has a beta of 0.403, suggesting its less volatile than the S&P 500 by 59.712%.

  • Which is a Better Dividend Stock SLS or OGEN?

    SELLAS Life Sciences Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLS or OGEN?

    SELLAS Life Sciences Group quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. SELLAS Life Sciences Group's net income of -$7.1M is lower than Oragenics's net income of -$2.5M. Notably, SELLAS Life Sciences Group's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group is -- versus 1.31x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLS
    SELLAS Life Sciences Group
    -- -- -- -$7.1M
    OGEN
    Oragenics
    1.31x -- -- -$2.5M
  • Which has Higher Returns SLS or TCRT?

    Alaunos Therapeutics has a net margin of -- compared to SELLAS Life Sciences Group's net margin of -28225%. SELLAS Life Sciences Group's return on equity of -- beat Alaunos Therapeutics's return on equity of -189.69%.

    Company Gross Margin Earnings Per Share Invested Capital
    SLS
    SELLAS Life Sciences Group
    -- -$0.10 --
    TCRT
    Alaunos Therapeutics
    -- -$0.70 $3.8M
  • What do Analysts Say About SLS or TCRT?

    SELLAS Life Sciences Group has a consensus price target of $6.83, signalling upside risk potential of 513.78%. On the other hand Alaunos Therapeutics has an analysts' consensus of -- which suggests that it could grow by 11008.1%. Given that Alaunos Therapeutics has higher upside potential than SELLAS Life Sciences Group, analysts believe Alaunos Therapeutics is more attractive than SELLAS Life Sciences Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLS
    SELLAS Life Sciences Group
    2 0 0
    TCRT
    Alaunos Therapeutics
    0 0 0
  • Is SLS or TCRT More Risky?

    SELLAS Life Sciences Group has a beta of 2.407, which suggesting that the stock is 140.73% more volatile than S&P 500. In comparison Alaunos Therapeutics has a beta of -0.385, suggesting its less volatile than the S&P 500 by 138.485%.

  • Which is a Better Dividend Stock SLS or TCRT?

    SELLAS Life Sciences Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alaunos Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group pays -- of its earnings as a dividend. Alaunos Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLS or TCRT?

    SELLAS Life Sciences Group quarterly revenues are --, which are smaller than Alaunos Therapeutics quarterly revenues of $4K. SELLAS Life Sciences Group's net income of -$7.1M is lower than Alaunos Therapeutics's net income of -$1.1M. Notably, SELLAS Life Sciences Group's price-to-earnings ratio is -- while Alaunos Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group is -- versus -- for Alaunos Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLS
    SELLAS Life Sciences Group
    -- -- -- -$7.1M
    TCRT
    Alaunos Therapeutics
    -- -- $4K -$1.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is ARK Next Generation Internet ETF a Good Investment?
Is ARK Next Generation Internet ETF a Good Investment?

The ARK Next Generation Internet ETF looks like a pretty…

Why Is Marvell Stock Up?
Why Is Marvell Stock Up?

Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…

Why Is General Electric Stock Going Up?
Why Is General Electric Stock Going Up?

General Electric Company, doing business these days as GE Aerospace…

Stock Ideas

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Sell
44
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
1
IONQ alert for Jan 10

IonQ [IONQ] is up 7.64% over the past day.

Sell
45
COLL alert for Jan 10

Collegium Pharmaceutical [COLL] is down 2.07% over the past day.

Sell
30
EDN alert for Jan 10

Empresa Distribuidora y Comercializadora Norte SA [EDN] is down 1.2% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock